2022 Drug Development Outsourcing Trends: A Shift to Functional Service Partnerships
As the drug development industry evolves, PPD is seeing a significant shift to outsourcing, specifically toward the use of functional service partnerships (FSPs). In this report, experts at PPD weigh in on questions surrounding:
Key industry challenges that have contributed to this shift to outsourcing
FSP market size and percentage of outsourcing observed
Ranked benefits of working with an FSP model
With these insights, drug developers will better understand what’s driving the shift to FSP services and why they should consider FSP as an outsourcing model.